Document is current
Any future updates will be listed below
-
Authors
Dong, Zhen https://orcid.org/0000-0002-3480-3421
Jiang, Wenhao https://orcid.org/0009-0000-9381-9848
Wu, Chunlong
Chen, Ting
Chen, Jiayi
Ding, Xuan https://orcid.org/0000-0002-4905-3061
Zheng, Shu https://orcid.org/0000-0002-2521-190X
Piatkevich, Kiryl D. https://orcid.org/0000-0002-7777-9468
Zhu, Yi https://orcid.org/0000-0003-0429-0802
Guo, Tiannan https://orcid.org/0000-0003-3869-7651
- License Information
-
More Information
Article History
Received: 9 May 2024
Accepted: 21 October 2024
First Online: 30 October 2024
Change Date: 19 January 2026
Change Type: Update
Change Details: Transparent Peer Review file and Source data were originally published with the wrong titles. The original article has been corrected.
Competing interests
: T.G. and Y.Z. are shareholders of Westlake Omics (Hangzhou) Biotechnology Co., Ltd., where ProteomEx and FAXP-related technologies are commercialized. T.G., Z.D., Y.Z., C.W., and K.D.P. are inventors of a granted patent (Chinese patent number: ZL 202310889444.4) submitted by Westlake Laboratory of Life Sciences and Biomedicine that cover the FAXP methods. The remaining authors declare no competing interests.
